Chronic Human Albumin Therapy Prolongs Survival in Patients with Decompensated Cirrhosis
Results from a clinical trial have led investigators to conclude adding longterm administration of human albumin to conventional treatment inpatients with decompensated cirrhosis appears to prolong survival.
Grifols’ Higher-Potency Rabies Immune Globulin Is Now Available
Grifols’ higher-potency rabies immune globulin (RIG), HyperRAB S/D, was made available to healthcare providers
Updated C. Diff Guidelines Reflect New Treatment Options and Recommendations
The Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) have updated guidelines for diagnosis and management of Clostridium difficile (C. diff).
CSL Behring Will Discontinue Carimune NF in Third Quarter 2018
Discontinuation of the product is due to the preference among healthcare professionals and patients for newer, more advanced immune globulin options.
VONVENDI Approved to Treat Von Willebrand Disease
The U.S. Food and Drug Administration has approved Shire’s VONVENDI, a recombinant von Willebrand factor treatment for perioperative management of bleeding in adults 18 years and older with von Willebrand disease.
Study Finds Antibiotics Can Weaken the Immune System
Researchers have found antibiotics can be counterproductive and weaken the immune system’s ability to fight off bacteria.
Gene Therapy for Hemophilia: Edging Closer to Reality
Potentially curative gene therapy is in the works for hemophilia.
Replacement Therapy for Hereditary Angioedema: Innovations Define a New Standard of Care
Hereditary angioedema is a rare genetic disease for which replacement therapy provides safe and highly effective treatment.
Expanding Uses of IVIG
Researchers are taking a closer look at intravenous immune globulin for its potential to stop the progression of multiple complex conditions from lupus to multiple sclerosis.
Co-Administration of Albumin with Lactulose Reverses Hepatic Encephalopathy and Reduces Mortality in Liver Cirrhosis
A multidisciplinary team of investigators based in New Delhi randomized 120 patients with liver cirrhosis and overt hepatic encephalopathy (HE) to receive oral lactulose therapy or oral lactulose plus 1.5 g/kg/day of human albumin. The primary study endpoint was complete reversal of HE; secondary endpoints included mortality and length of hospital stay.